I hereby certify that this correspondence is being deposited with the United Attorney Docket No.: 016303-005

Assistant Commissioner for Patents Washington, D.C. 20231

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Sean C. Semple, et al.

Application No.: 09/122,588

Filed: July 23, 1998

For: LIPOSOMAL COMPOSITIONS FOR THE DELIVERY OF NUCLEIC ACID

**CATALYSTS** 

**Assistant Commissioner for Patents** Washington, D.C. 20231

ATTN: Customer Correction Branch

**Application Processing Division** 

Sir:

Attached is a copy of the official Filing Receipt received from the Patent and

Trademark Office in the above-noted application for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that the priority data was omitted and should read as follows:

-- CONTINUING DATA AS CLAIMED BY APPLICANT-

PROVISIONAL APPLICATION NO. 60/053,813 07/24/97 ---



Examiner:

M. Schmidt

Art Unit:

1635

REQUEST FOR CORRECTED FILING

RECEIPT

Attorney Docket .: 016303-005310 Application No.: 99/122,588

Page 2



The correction is not due to any error by applicants, and no fee is due.

Respectfully submitted,

Lugenja Garretti Wackowsk Reg. Nd. 37,330

TOWNSEND and TOWNSEND and CREW LI

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

EGW/lls

SF 1081069 v1

016303-00531043

PTO-103X-(Rev: 8:95)

FILING RECEIPT

CORRECTED



UNITED STATES PARTMENT OF COMMERCE Patent and Transmark Office ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER PART OF GRP ART UNIT FIL FEE REC'D ATTORNEY DOCKET NO. DRWGS TOT CL IND CI

09/122,588

07/23/98

1644

\$2,487.00 016303-00531

14 194

3

020350 TOWNSEND AND TOWNSEND AND CREW TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO CA 94111

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

SEAN C. SEMPLE, VANCOUVER, CANADA; SÁNDRA K. KLÍMUK, NORTH VANCOUVER, CANADA; PETER SCHERRER, VANCOUVER, CANADA; MICHAEL J. HOPE, VANCOUVER, CANADA; YUAN-PENG ZHANG, VANCOUVER, CANADA; MARK REYNOLDS, LAFAYETTE, CO; JOHN MIN, BOULDER, CO.

CONTINUING DATA AS CLAIMED BY APPLICANT-PROVISIONAL APPLICATION NO. 60/053, 813 07/24/97

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 08/20/98
TITLE
LIPOSOMAL COMPOSITIONS FOR THE DELIVERY OF NUCLEIC ACID CATALYSTS

PRELIMINARY CLASS: 424

99 APR 13 AH 8: 09
RECEIVED

DATA ENTRY BY: BATIE, MARGARET

TEAM: 01 DATE: 04/07/99





Bib Data Sheet



Address: COMMISSIONER OF PATENTS AND TRADILMARKS Washington, D.C. 20231

SERIAL NUMBE 09/122,588	ER	07/23/1998 RULE _	С	LASS GROUP ART 424 1635		UNIT	NIT DOCKET 016303-00		
SANDRA K. PETER SCH MICHAEL J. YUAN-PENG MARK REYI JOHN MIN, *** CONTINUING I THIS APPLI *** FOREIGN APP	. KLIM HERF . HOF G ZH, NOLE BOUI DATA N CLI	AIMS BENEFIT OF 60 TIONS ************************************	UVER, C ANADA; NADA; CANADA;	<b>\</b> ;		,			
Foreign Priority claimed				STATE OR COUNTRY CANADA		, .		AL MS	INDEPENDENT CLAIMS 3
<b>ADDRESS</b> 20350				_					
TITLE					***********				
LIPOSOMAL CON	MPOS	SITIONS FOR THE DE	LIVERY	OF NUCLEIC	ACID	CATALY	STS		
		Authority has been gi			All Fees  1.16 Fees (Filing)  1.17 Fees (Processing Ext. of				
RECEIVED N 2487	No to charge/credit DEPOSIT ACCOUNT No for following:					time)			
						1.18 Fees (Issue)			
						Other			
	∥ <b>⊔</b> Credit						II <b>L</b>	. However, or	j godgener name - er romannegen muser og